Breaking News Instant updates and real-time market news.

DAL

Delta Air Lines

$51.47

-0.89 (-1.70%)

, BBBY

Bed Bath & Beyond

$21.50

0.27 (1.27%)

08:59
04/12/18
04/12
08:59
04/12/18
08:59

On The Fly: Pre-market Movers

HIGHER: Bellicum Pharmaceuticals (BLCM), up 20% after the FDA lifted the hold on the company's BPX-501 study... QuinStreet (QNST), up 10% after pre-announcing a preliminary Q3 revenue beat and responding to allegations made against the company by short-seller Kerrisdale Capital... Globalstar (GSAT), up 6% after Mudrick Capital Management disclosed a 5.6% activist stake and said it was willing to lend the company $150M to help address the company's capital needs. UP AFTER EARNINGS: Delta (DAL), up 2%... Rite Aid (RAD), up 2%. DOWN AFTER EARNINGS: Bed Bath & Beyond (BBBY), down 17%... Apogee Enterprises (APOG), down 7%. ALSO LOWER: PolarityTE (COOL), down 12% after filing to sell common stock... Novavax (NVAX), down 17% after the company's 30.3M share spot secondary offering priced at $1.65 per share... Ellie Mae (ELLI), down 3% after Wedbush analyst Jason Weaver downgraded the stock to Underperform from Neutral.

DAL

Delta Air Lines

$51.47

-0.89 (-1.70%)

BBBY

Bed Bath & Beyond

$21.50

0.27 (1.27%)

BLCM

Bellicum Pharmaceuticals

$6.85

0.1 (1.48%)

QNST

QuinStreet

$10.14

-2.18 (-17.69%)

COOL

Ticker changed to PTE

$18.31

-0.8 (-4.19%)

GSAT

Globalstar

$0.81

0.0965 (13.55%)

ESND

Essendant

$8.47

-0.11 (-1.28%)

GPC

Genuine Parts

$89.66

-0.71 (-0.79%)

RAD

Rite Aid

$1.64

-0.01 (-0.61%)

ELLI

Ellie Mae

$94.00

-0.93 (-0.98%)

APOG

Apogee Enterprises

$42.46

0.01 (0.02%)

  • 12

    Apr

  • 12

    Apr

  • 12

    Apr

  • 17

    Apr

  • 19

    Apr

  • 24

    Apr

  • 26

    Apr

  • 08

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 30

    May

  • 12

    Jun

  • 29

    Jun

  • 12

    Apr

DAL Delta Air Lines
$51.47

-0.89 (-1.70%)

01/26/18
COWN
01/26/18
NO CHANGE
COWN
Airline sector weakness a buying opportunity, says Cowen
Cowen analyst Helane Becker noted airline stocks came under pressure as investors grew concerned about capacity growth by United Continental (UAL) and fears it would destroy the fare structure. The analyst noted the capacity growth is in small markets where they might make a difference but that RASM is up year-over-year. Becker would be a buyer of Alaska Air (ALK), Delta Air (DAL), American Airlines (AAL) and Southwest Air (LUV) on the pullback, but would avoid United Continental shares.
02/28/18
STFL
02/28/18
NO CHANGE
Target $90
STFL
Buy
Delta Air Lines price target raised to $90 from $85 at Stifel
Stifel analyst Joseph DeNardi raised his price target for Delta Air Lines to $90 after reviewing the company's annual filing. The price target represents a new high on the Street, according to Bloomberg. The analyst cites stronger growth from Delta's loyalty program for the target raise. His sum-of-the-parts analysis values the core airline at seven times 2019 earnings and the loyalty program at 22 times. DeNardi keeps a Buy rating on Delta Air Lines.
03/09/18
JPMS
03/09/18
NO CHANGE
JPMS
JPMorgan sees Airlines raising Q1 outlooks at next week's conference
JPMorgan analyst James Baker believes several Airlines will raise their Q1 guidance at his firm's Aviation, Transportation and Industrials Conference next week. He expects near-term consensus estimates to move higher for the airlines coming out of the presentations, particularly for United Continental (UAL). The analyst recommends increasing exposure to the sector ahead of the conference. He raised his estimates for United the most, taking his Q1 earnings per share forecast up to 32c from 3c. Other names in the space include American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU) and Southwest (LUV).
04/05/18
STFL
04/05/18
NO CHANGE
Target $100
STFL
Buy
Delta Air Lines price target raised to $100 from $90 at Stifel
Stifel analyst Joseph DeNardi raised his price target for Delta Air Lines to $100 from $90 on valuation. The analyst reiterates a Buy rating on the shares given Delta's combination of peer-leading operating margins, an investment grade balance sheet, structural advantages related to the location of its hubs and greater labor flexibility.
BBBY Bed Bath & Beyond
$21.50

0.27 (1.27%)

04/12/18
MSCO
04/12/18
NO CHANGE
Target $16
MSCO
Underweight
Bed Bath & Beyond price target lowered to $16 from $20 at Morgan Stanley
Morgan Stanley analyst Simeon Gutman said he is not convinced Bed Bath & Beyond's revenue will respond to the company's initiatives. Beyond a lift from the Babies R' Us bankruptcy, it is hard for him to see how the company can drive positive same-store sales without the aid of promotions, Gutman tells investors. He maintains an Underweight rating on Bed Bath shares and lowered his price target on the stock to $16 from $20.
04/12/18
FBCO
04/12/18
NO CHANGE
Target $20
FBCO
Neutral
Bed Bath & Beyond price target lowered to $20 from $25 at Credit Suisse
Credit Suisse analyst Seth Sigman lowered his price target for Bed Bath & Beyond to $20 from $25 as the company's strategic plan is clear, but margin level leaves little room for error. The analyst reiterates a Neutral rating on the shares.
04/12/18
WEDB
04/12/18
NO CHANGE
Target $18
WEDB
Neutral
Bed Bath & Beyond price target lowered to $18 from $23 at Wedbush
Wedbush analyst Seth Basham lowered his price target for Bed Bath & Beyond to $18 from $23 as he expects heavy investments to continue with payoff still unclear. The analyst reiterates a Neutral rating on the shares.
04/12/18
JPMS
04/12/18
NO CHANGE
Target $16
JPMS
Underweight
Bed Bath & Beyond price target lowered to $16 from $18 at JPMorgan
JPMorgan analyst Christopher Horvers lowered his price target for Bed Bath & Beyond to $16 saying the company's negative comps in both Q4 ending and over the past two quarters are "particularly disappointing." As is the acceleration in gross margin declines, Horvers tells investors in a post-earnings research note. He believes the "pressure on the model" and competitive environment are evident in Bed Bath's 19% guide below the Street for 2018. The analyst keeps an Underweight rating on the shares.
BLCM Bellicum Pharmaceuticals
$6.85

0.1 (1.48%)

03/14/18
JEFF
03/14/18
NO CHANGE
Target $16
JEFF
Buy
Bellicum clinical hold should lift soon, says Jefferies
Jefferies analyst Biren Amin says Bellicum Pharmaceuticals last night provided an update of its leading prgm BPX-501 with an "encouraging" survival rate at one year in pediatric acute myeloid leukemia patients. For BPX-601, management reported CART cell expansion in one pancreatic cancer patient following rimiducid administration, providing first patient validation of the company's activation switch, Amin tells investors in a post-earnings research note. The analyst notes Bellicum has also responded to FDA including proposed protocol changes. Amin believes the clinical hold should lift soon and keeps a Buy rating on Bellicum Pharmaceuticals with a $16 price target.
04/11/18
WELS
04/11/18
UPGRADE
WELS
Outperform
Bellicum Pharmaceuticals upgraded to Outperform at Wells Fargo
04/12/18
WELS
04/12/18
UPGRADE
Target $23
WELS
Outperform
Wells Fargo upgrades Bellicum to Outperform on lifting of clinical hold
Wells Fargo analyst Jim Birchenough last night upgraded Bellicum Pharmaceuticals to Outperform from Market Perform and raised his price target for the shares to $23 from $6. The shares in premarket trading are up 27% to $8.70 following news that the FDA lifted the clinical hold on studies of BPX-501 in the U.S. Rapid resolution of the clinical hold "substantially de-risks the investment," Birchenough tells investors in a research note. He believes Bellicum's platform for controllable cell therapies is well positioned for therapeutic oncology indications.
04/12/18
CANT
04/12/18
NO CHANGE
Target $18
CANT
Overweight
Bellicum price target raised to $18 from $10 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Bellicum Pharmaceuticals to $18 following the announcement of the FDA's lift of its U.S. clinical hold for BPX-501. The analyst now has increased confidence across the BPX-501 platform. He reiterates an Overweight rating on the shares.
QNST QuinStreet
$10.14

-2.18 (-17.69%)

11/28/17
BRRR
11/28/17
INITIATION
Target $12.5
BRRR
Outperform
QuinStreet initiated with an Outperform at Barrington
Barrington analyst James Goss started QuinStreet with an Outperform rating and $12.50 price target. The analyst sees the company's education sector growing now that regulatory pressures are easing.
04/12/18
SPHN
04/12/18
NO CHANGE
Target $13
SPHN
Overweight
Stephens more positive on QuinStreet after pre-announcement, rebuttal
Stephens analyst John Campbell noted that he'd already believed that yesterday's short report turbulence in QuinStreet was a buying opportunity, but following the company's pre-announcement of a "sizable" Q3 beat and its willingness to defend itself against what he sees as "meritless claims" he is incrementally more positive. Campbell, who said he would be a "strong" buyer of QuinStreet here, raised his price target on the stock to $13 from $11.50 and keeps an Overweight rating on the shares.
04/12/18
BRRR
04/12/18
NO CHANGE
Target $15
BRRR
Outperform
QuinStreet short report creates buying opportunity, says Barrington
Barrington analyst James Goss says the 20% pullback yesterday in shares of QuinStreet following a short report "sets up a substantial buying opportunity." The key figure in last night's Q3 preannouncement was revenue growth that "well exceeded" estimates heading into the quarter, Goss tells investors in a research note. He believes QuinStreet's full-year guidance appears "increasingly conservative." The analyst keeps an Outperform rating on the shares with a $15 price target.
04/11/18
SPHN
04/11/18
NO CHANGE
Target $11.5
SPHN
Overweight
QuinStreet short report repeats old claims, says Stephens
Stephens analyst John Campbell said Kerrisdale Capital's newly published short report about QuinStreet repeats many of the same items seen in past short reports. However, he believes the company is still growing nicely ex-large client gains and acquired revenue, "sharply" expanding margins and continues to be a takeout candidate. Campbell, who views today's weakness as "a great buying window," keeps an Overweight rating and $11.50 price target on QuinStreet shares.
COOL Ticker changed to PTE
$18.31

-0.8 (-4.19%)

02/14/18
CANT
02/14/18
INITIATION
Target $70
CANT
Overweight
PolarityTE initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated PolarityTE with an Overweight and $70 price target.
02/15/18
CANT
02/15/18
INITIATION
Target $70
CANT
Overweight
Cantor says PolarityTE can revolutionize regenerative medicine
Cantor Fitzgerald analyst Elemer Piros last night initiated PolarityTE with an Overweight rating and $70 price target. The analyst believes the company can revolutionize the field of regenerative medicine. He thinks PolarityTE's SkinTE autologous cell product can achieve $600M of sales in wound healing and potentially "multiples of this number" when adding the bone, cartilage, heart and muscle products in development.
02/15/18
02/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Portland General Electric (POR) initiated with a Buy at Mizuho. 2. Arsanis (ASNS) initiated with an Overweight at Cantor Fitzgerald. 3. Cantor says PolarityTE (COOL) can revolutionize regenerative medicine. 4. Foundation Medicine (FMI) initiated with an Outperform at Cowen. 5. Box (BOX) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GSAT Globalstar
$0.81

0.0965 (13.55%)

04/11/18
MSCO
04/11/18
INITIATION
Target $0.7
MSCO
Equal Weight
Globalstar initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Simon Flannery started Globalstar with an Equal Weight rating and 70c price target, stating that the company has the company has significant near-term funding needs, is highly levered and progress on unlocking value from its portfolio of wireless spectrum has been slow.
ESND Essendant
$8.47

-0.11 (-1.28%)

GPC Genuine Parts
$89.66

-0.71 (-0.79%)

09/25/17
RBCM
09/25/17
NO CHANGE
RBCM
Genuine Parts acquisition of Alliance makes strategic sense, says RBC
RBC Capital analyst Scot Ciccarelli maintained a Sector Perform rating on Genuine Parts, saying that while the company's agreement to acquire Alliance Automotive Group for $2.0B makes strategic sense, Genuine Parts' high valuation relative to its organic earnings leaves Ciccarelli "on the sidelines." RBC did, however, raise its price target on Genuine Parts to $98 from $85 after the acquisition announcement.
10/20/17
GABE
10/20/17
NO CHANGE
GABE
Buy
Genuine Parts weakness a buying opportunity, says Gabelli
Gabelli analyst Brian Sponheimer recommend investors use expected weakness in Genuine Parts to Buy more shares following the "disappointing" Q3 report. The analyst said regional and category-related sales weakness provide sufficient evidence that 2017's difficulties will turn out to be more transitory. Further, Sponheimer views the company's Alliance Automotive Group acquisition as a natural extension of its successful growth strategy and believes the company to have several avenues for acquisition opportunities in the years ahead.
12/04/17
MOFT
12/04/17
INITIATION
MOFT
Sell
Genuine Parts initiated with a Sell at MoffettNathanson
02/21/18
RBCM
02/21/18
NO CHANGE
Target $100
RBCM
Sector Perform
Genuine Parts price target lowered to $100 from $107 at RBC Capital
RBC Capital analyst Scot Ciccarelli lowered his price target on Genuine Parts to $100 after the company's Q4 results and lower than expected FY18 outlook. The analyst notes that while the Industrial business exceeded expectations, Office/Business Products segment continues to deteriorate. Ciccarelli keeps his Sector Perform rating based on the soft OBP and the cyclicality of the Industrial business.
RAD Rite Aid
$1.64

-0.01 (-0.61%)

02/13/18
LEER
02/13/18
NO CHANGE
LEER
Walgreens may seek to acquire AmerisourceBergen sooner than expected, says Leerink
Leerink analyst David Larsen notes that The Wall Street Journal reported that Walgreens (WBA) has approached AmerisourceBergen (ABC) about a potential takeover. The analyst is surprised that talks of such a large transaction have surfaced so quickly following the Rite Aid (RAD) deal, but says he has always believed that Walgreens at some point would seek to acquire either Express Scripts (ESRX) or AmerisourceBergen. Given the broad-based speculation in the business press about this deal, it is possible shares of Express Scripts will trade off, Larsen contends.
01/04/18
EVER
01/04/18
INITIATION
Target $1.5
EVER
Underperform
Rite Aid initiated with an Underperform at Evercore ISI
Evercore ISI started Rite Aid with an Underperform rating and $1.50 price target.
01/04/18
COWN
01/04/18
NO CHANGE
Target $3
COWN
Outperform
Rite Aid Q3 results better than expected, says Cowen
Cowen analyst Charles Rhyee said Rite Aid's Q3 results were better than expected and he believes its Envison Rx will stabilize in 2019. He also noted management commentary was positive and suggested upside potential due to early relief in generic pricing beginning in 2019. Ryhee reiterated his Outperform rating and raised his price target to $2.50 from $2.15 on Rite Aid shares.
02/20/18
EVER
02/20/18
NO CHANGE
Target $1.5
EVER
Underperform
Rite Aid transaction valued at 75c-$1.75 per share, says Evercore ISI
Evercore ISI analyst Ross Muken estimates the value per Rite Aid share to be 75c- $1.75 depending on the elections made by Rite Aid shareholders under the company's announced agreement with Albertson's. His estimate is based on the pro-forma company's "potentially generous" $3.7 B in EBITDA at an EV/EBITDA multiple of 6.8x, he explains. Muken keeps an Underperform rating on Rite Aid with a $1.50 price target. In early trading, Rite Aid shares are up 3c, or 1.6%, to $2.16.
ELLI Ellie Mae
$94.00

-0.93 (-0.98%)

04/12/18
04/12/18
DOWNGRADE
Target $69

Underperform
Ellie Mae downgraded to Underperform at Wedbush
As previously reported, Wedbush analyst Jason Weaver downgraded Ellie Mae to Underperform from Neutral based upon what is shaping up to be a disappointing year for mortgage originations in 2018, as well as some amount of skepticism around the company's ability to achieve its long-term growth and profitability targets in what is increasingly a maturing market for mortgage loan origination systems and a challenging market for their customers. The analyst also lowered his price target on the shares to $69 from $90.
04/12/18
WEDB
04/12/18
DOWNGRADE
WEDB
Underperform
Ellie Mae downgraded to Underperform from Neutral at Wedbush
03/21/18
JPMS
03/21/18
NO CHANGE
Target $112
JPMS
Overweight
Ellie Mae long-term targets achievable, says JPMorgan
JPMorgan analyst Sterling Auty believes Ellie Mae at yesterday's analyst day struck a positive note in terms of both the near and long-term outlook. The company is targeting to deliver $1B in revenue by 2022-2023, implying 20% annual growth. These long-term targets are achievable given Ellie Mae's large market opportunity, Auty tells investors in a research note. He keeps an Overweight rating on the shares with a $112 price target.
03/16/18
KEYB
03/16/18
NO CHANGE
Target $120
KEYB
Overweight
Ellie Mae shares are 'undervalued and underappreciated,' says KeyBanc
KeyBanc analyst Brent Bracelin thinks 2018 should be the year that Ellie Mae shares "break out from the investor perception that its growth trajectory could be eroded by rising interest rates." New subscription revenue, incremental transactional revenue and the company's digital mortgage initiatives should drive accelerated growth in 2018, Bracelin tells investors in a research note titled "Underappreciated and Undervalued." He keeps an Overweight rating on Ellie Mae with a $120 price target.
APOG Apogee Enterprises
$42.46

0.01 (0.02%)

04/04/18
GSCO
04/04/18
DOWNGRADE
Target $39
GSCO
Sell
Apogee Enterprises downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Samuel Eisner downgraded Apogee Enterprises to Sell and cut his price target for the shares to $39 from $44. The analyst believes "cyclical maturity" and margin risk warrant caution on the shares. Goldman expects private non-residential construction growth to flatten in 2018 and 2019, which makes Apogee's returns outlook less attractive relative to peers, Eisner tells investors in a research note.
08/24/17
DADA
08/24/17
NO CHANGE
DADA
Apogee Enterprises weakness overdone, says DA Davidson
DA Davidson analyst Brent Thielman says that the reduction in Apogee's fiscal 2018 guidance "raises concerns" about its "M&A and mid-size glass market penetration strategies." However, the analyst thinks that the weakness in the stock was overdone, and he remains upbeat on the company's fiscal 2019 outlook. The analyst cut his price target on the stock to $52 from $65 but keeps a Buy rating on the shares.
05/25/17
SIDC
05/25/17
INITIATION
SIDC
Buy
Apogee Enterprises re-initiated with a Buy at Sidoti
04/17/17
CHLM
04/17/17
NO CHANGE
Target $68
CHLM
Buy
Apogee Enterprises pullback creates buying opportunity, says Craig-Hallum
Craig-Hallum analyst Eric Stine notes that Apogee Enterprises reported "solid 4Q results," but points out that the pullback on misplaced concerns over non-re construction cycle due to 2018 revenue guidance creates a buying opportunity. The analyst reiterates a Buy rating and $68 price target.

TODAY'S FREE FLY STORIES

BAYRY

Bayer

$0.00

(0.00%)

15:19
11/20/18
11/20
15:19
11/20/18
15:19
Hot Stocks
Bayer granted FDA orphan designation for Hemophilia A treatment »

Bayer was granted FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILI

Bilibili

$13.68

0.65 (4.99%)

15:19
11/20/18
11/20
15:19
11/20/18
15:19
Options
Bilibili options imply 19.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
11/20/18
11/20
15:17
11/20/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENE

Xenon Pharmaceuticals

$8.18

0.12 (1.49%)

15:16
11/20/18
11/20
15:16
11/20/18
15:16
Hot Stocks
Xenon granted orphan designation for alternating hemiplegia treatment »

Xenon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
11/20/18
11/20
15:16
11/20/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCG

Scana

$44.14

0.44 (1.01%)

, D

Dominion

$74.55

0.15 (0.20%)

15:12
11/20/18
11/20
15:12
11/20/18
15:12
Hot Stocks
Scana higher as Dominion offers alternate deal plan to South Carolina PSC »

According to a new filing…

SCG

Scana

$44.14

0.44 (1.01%)

D

Dominion

$74.55

0.15 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACHN

Achillion

$2.89

0.11 (3.96%)

15:10
11/20/18
11/20
15:10
11/20/18
15:10
Options
Second day of call buying in Achillion Pharma »

Second day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXRT

NexPoint Residential

$36.26

0.93 (2.63%)

15:06
11/20/18
11/20
15:06
11/20/18
15:06
Hot Stocks
NexPoint Residential VP Matt McGraner buys over $313K in company shares »

NexPoint Residential VP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMWYY

BMW

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

15:04
11/20/18
11/20
15:04
11/20/18
15:04
Periodicals
Trump plans talks with German car executives, Bloomberg says »

The White House has…

BMWYY

BMW

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$24.91

-0.535 (-2.10%)

15:04
11/20/18
11/20
15:04
11/20/18
15:04
Options
Gap options imply 11.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

D

Dominion

$74.65

0.25 (0.34%)

, SCG

Scana

$44.08

0.38 (0.87%)

15:01
11/20/18
11/20
15:01
11/20/18
15:01
Periodicals
Dominion proposes alternate plan for Scana deal, Bloomberg says »

Bloomberg cites an…

D

Dominion

$74.65

0.25 (0.34%)

SCG

Scana

$44.08

0.38 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$11.27

-0.865 (-7.13%)

15:00
11/20/18
11/20
15:00
11/20/18
15:00
Options
Active trading in US Oil Fund options as crude oil drops 7% »

Active trading in US Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
11/20/18
11/20
15:00
11/20/18
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

HIMX

Himax

$4.05

-0.075 (-1.82%)

14:56
11/20/18
11/20
14:56
11/20/18
14:56
Downgrade
Himax rating change  »

Himax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 05

    Dec

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Durable Goods Preview »

U.S. Durable Goods…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Existing Home Sales Preview »

U.S. Existing Home Sales…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Michigan Consumer Sentiment Preview »

U.S. Michigan Consumer…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Leading Indicators Preview »

U.S. Leading Indicators…

FB

Facebook

$131.60

-0.02 (-0.02%)

14:53
11/20/18
11/20
14:53
11/20/18
14:53
Periodicals
Dashboard to track time wasted on Facebook starts roll out, Venture Beat says »

Facebook has confirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

HIMX

Himax

$4.05

-0.075 (-1.82%)

14:52
11/20/18
11/20
14:52
11/20/18
14:52
Downgrade
Himax rating change  »

Himax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 05

    Dec

XRT

S&P Retail Index SPDR

$44.32

-1.2 (-2.64%)

14:50
11/20/18
11/20
14:50
11/20/18
14:50
Options
SPDR Retail Trust options are active ahead of Black Friday »

SPDR Retail Trust options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$122.41

-3.34 (-2.66%)

14:49
11/20/18
11/20
14:49
11/20/18
14:49
Options
Autodesk options imply 12.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

  • 04

    Dec

EQT

EQT Corporation

$16.81

-0.25 (-1.47%)

14:45
11/20/18
11/20
14:45
11/20/18
14:45
Options
EQT Corporation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$15.78

-0.635 (-3.87%)

14:35
11/20/18
11/20
14:35
11/20/18
14:35
Options
Fiat Chrysler put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDX

Celldex

$0.31

-0.0002 (-0.06%)

14:32
11/20/18
11/20
14:32
11/20/18
14:32
Hot Stocks
Celldex announces launch of Chase Offers »

Cardlytics announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.